Nitrate reactive structural gene mutants of Aspergillus nidulans

Two strains characterized as niaD structural gene mutants in Aspergillus nidulans produce a nitrate reductase which retains the ability to react with nitrate while lacking the ability to oxidize its naturally occurring substrate NADPH. Fifteen such nitrate reactive niaD strains exhibited strong interallelic complementation when tested against strains bearing point mutations in eleven other loci essential to induction and synthesis of nitrate reductase in Aspergillus. Fourteen representatives of this phenotype formed enzyme with a molecular weight equivalent to that of the wild type (200 kD) and also remained inducible by nitrate and repressible by ammonium. The mutation appears to alter the NADPH binding domain of the nitrate reductase since the affinity for the dinucleotide fold in Affigel blue and the dissociation constant (Ks) for enzyme isolated from the mutants on the basis of reduced methyl viologen-nitrate reductase activity is significantly less than that observed for the native enzyme from the wild type.     

Dopamine-beta-hydroxylase activity in plasma obtained from the pulmonary artery and left ventricle of man

Dopamine-β-hydroxylase activity (DBH) has been measured in plasma obtained simultaneously from the pulmonary artery and left ventricle of fourteen patients who underwent diagnostic cardiac catheterisation. In the majority of these subjects the levels of enzyme activity in the arterial and venous blood were similar, indicating that inactivation of DBH had not occurred in its passage through the pulmonary circulation. One patient with pulmonary hypertension had a large a-v difference in enzyme activity that may have been caused by altered pulmonary haemodynamics. Three of the five subjects that undertook a standardised exercise test on a bicycle ergometer showed a significant increase in plasma DBH activity. There was no correlation between the increases in DBH activity and in cardiac index and heart rate.     

Unprecedented Therapeutic Potential with a Combination of A2A/NR2B Receptor Antagonists as Observed in the 6-OHDA Lesioned Rat Model of Parkinson's Disease

In Parkinson''s disease, the long-term use of dopamine replacing agents is associated with the development of motor complications; therefore, there is a need for non-dopaminergic drugs. This study evaluated the potential therapeutic impact of six different NR2B and A_2A receptor antagonists given either alone or in combination in unilateral 6-OHDA-lesioned rats without (monotherapy) or with (add-on therapy) the co-administration of L-Dopa: Sch-58261+ Merck 22; Sch-58261+Co-101244; Preladenant + Merck 22; Preladenant + Radiprodil; Tozadenant + Radiprodil; Istradefylline + Co-101244. Animals given monotherapy were assessed on distance traveled and rearing, whereas those given add-on therapy were assessed on contralateral rotations. Three-way mixed ANOVA were conducted to assess the main effect of each drug separately and to determine whether any interaction between two drugs was additive or synergistic. Additional post hoc analyses were conducted to compare the effect of the combination with the effect of the drugs alone. Motor activity improved significantly and was sustained for longer when the drugs were given in combination than when administered separately at the same dose. Similarly, when tested as add-on treatment to L-Dopa, the combinations resulted in higher levels of contralateral rotation in comparison to the single drugs. Of special interest, the activity observed with some combinations could not be described by a simplistic additive effect and involved more subtle synergistic pharmacological interactions. The combined administration of A_2A/NR2B-receptor antagonists improved motor behaviour in 6-OHDA rats. Given the proven translatability of this model such a combination may be expected to be effective in improving motor symptoms in patients.